stoxline Quote Chart Rank Option Currency Glossary
  
Kiora Pharmaceuticals, Inc. (KPRX)
0.706  0.092 (15%)    03-28 16:00
Open: 0.6
High: 0.72
Volume: 580,577
  
Pre. Close: 0.6139
Low: 0.6
Market Cap: 19(M)
Technical analysis
2024-03-28 4:52:34 PM
Short term     
Mid term     
Targets 6-month :  0.87 1-year :  1.02
Resists First :  0.75 Second :  0.87
Pivot price 0.62
Supports First :  0.61 Second :  0.53
MAs MA(5) :  0.62 MA(20) :  0.63
MA(100) :  0.59 MA(250) :  1.03
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  62.7 D(3) :  47.3
RSI RSI(14): 60.9
52-week High :  5.25 Low :  0.46
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ KPRX ] has closed Bollinger Bands are 8.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.72 - 0.72 0.72 - 0.73
Low: 0.59 - 0.6 0.6 - 0.6
Close: 0.7 - 0.71 0.71 - 0.71
Company Description

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Headline News

Thu, 28 Mar 2024
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 ... - Yahoo Finance

Thu, 28 Mar 2024
Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Rating Reaffirmed by HC Wainwright - Defense World

Mon, 25 Mar 2024
Kiora Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary - TradingView

Mon, 25 Mar 2024
Kiora Pharmaceuticals reports FY results - Seeking Alpha

Mon, 25 Mar 2024
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases - Yahoo Finance

Fri, 22 Mar 2024
Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Down 3.8% - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 23 (M)
Shares Float 6 (M)
Held by Insiders 0.9 (%)
Held by Institutions 19.6 (%)
Shares Short 57 (K)
Shares Short P.Month 350 (K)
Stock Financials
EPS 0.77
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.04
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -38.5 %
Return on Equity (ttm) -136.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.44
Qtrly Earnings Growth 0 %
Operating Cash Flow -9 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio 0.9
PEG Ratio 0
Price to Book value 0.67
Price to Sales 0
Price to Cash Flow -1.83
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android